Effects of Vitamin D in Parkinson's Disease (PD)
The Effects of Vitamin D on Balance in Persons With PD
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- VA Portland Health Care System, Portland, OR
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Parkinson's disease;
- ability to ambulate 50 feet;
- ability to cooperate with balance testing;
- vitamin D level less than 40ng/ml;
- balance problems;
- ability to walk 50 feet without the help of another person
Exclusion Criteria:
- MMSE < 25;
- another neurological or orthopedic deficit that in the examiner's opinion would affect testing;
- history of renal stones or hypercalcemia;
- unwillingness to not be on other vitamin D supplementation during the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Arm 1
Will be on high dose vitamin D3 (10,000 IU daily) and 1000 mg of calcium
|
Vitamin D3 at 10,000 IU a day
1000mg calcium daily
|
|
Comparatore placebo: Arm 2
Will be on placebo and 1000mg of calcium.
|
1000mg calcium daily
A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Static Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 1-3)
Lasso di tempo: Baseline, 16 weeks
|
Sensory organization test (SOT) is a form of posturography.
which is designed to assess quantitatively an individual's ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance.
The SOT measures sway during 6 scenarios.
In scenarios 1-3 the base is stable and eyes are open, then closed, and then the visual surround moves.
SOT 1-3 is an average measurement of equilibrium - the average center of gravity sway for each condition.
It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Ambulatory Balance Measured by Instrumented Timed up and go (iTUG) Turn Duration
Lasso di tempo: Baseline and 16 weeks
|
This is a test that measures ambulatory balance and mobility.
The instrumented timed up and go (iTUG) is an average time (seconds) of three trials that involve the participant arising from a chair, walking 25 feet turning around, walking back to the chair, and sitting down.
The turn duration is the average time to turn at the end of the 25 foot walk.
Longer duration of time (seconds) indicates more rigidity, a proxy measure for "ON" time in Parkinson's disease.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline and 16 weeks
|
|
Change in Strength as Recorded by Measuring Knee Flexion Using Biodex (Total Work)
Lasso di tempo: Baseline, 16 weeks
|
Defined as the total muscular force output for the repetition with the greatest amount of work.
The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Dynamic Balance as Recorded Using Dynamic Posturography With the Sensory Organization Test (SOT 4-6)
Lasso di tempo: Baseline, 16 weeks
|
Sensory organization test (SOT) is a form of posturography.
which is designed to assess quantitatively an individual's ability to use visual, proprioceptive and vestibular cues to maintain postural stability in stance.
The SOT measures sway during 6 scenarios.
In 4-6 the base moves and the subject has eyes open, then closed, then the visual surround moves.
SOT 4-6 is an average measurement of equilibrium - the average center of gravity sway for each condition.
It generates a score of 0 (fall) up to 100 for each scenario and an overall composite score.
Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
|
Change in Strength as Recorded by Measuring Knee Extension Using Biodex (Total Work)
Lasso di tempo: Baseline, 16 weeks
|
Defined as the total muscular force output for the repetition with the greatest amount of work.
The equation for work is: W = F x D. Change score is measurement at 16 weeks minus measurement at baseline.
|
Baseline, 16 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Cognition (Trail Making Test B-A)
Lasso di tempo: Baseline, 16 weeks
|
The Trail Making Test (TMT) consists of two parts (A & B) in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.
The test provides information about visual search speed, scanning, speed of processing, and executive functioning.
Part A measures processing speed and part B measures executive functioning.
The TMT is time to complete each part of the test in seconds.
Higher scores indicate greater impairment.
Subtracting part A from part B is theorized to reduce the influence of the working memory and visuospatial demands and, therefore, provides a relatively pure indicator of executive function.
Change score is measurement (Part B - Part A) at 16 weeks minus measurement (Part B - Part A) at baseline, negative scores indicate a improvement in executive functioning.
|
Baseline, 16 weeks
|
|
Change in Quality of Life as Recorded Using Quality of Life Scales (PDQ39)
Lasso di tempo: Baseline, 16 weeks
|
The PDQ39 is a 39 item patient completed survey targeting well-being and functioning in PD.
This scale address 8 dimensions (mobility, activities of daily living, emotional well-being, stigma, social support, cognitions, communication, and bodily discomfort).
The PDQ39 dimension scores are on a scale of 0 ("Never") to 4 ("Always/Cannot Do").
Scale scores are summed and range from 0 to 100 with 100 being the maximum level of problems.
For a single index figure to characterize the impact of Parkinson's disease upon PD patients (PDSI), all 39 items of the PDQ39 can be summed.
The PDQ39 and the use of a PDSI have shown adequate reliability and convergent validity.
Change score is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in quality of life.
|
Baseline, 16 weeks
|
|
Change in Parkinsonism as Measured by the UPDRS
Lasso di tempo: Baseline, 16 weeks
|
This is the motor subsection of the UPDRS and is a commonly used tool to rate the symptoms of Parkinson's disease.
This scale rates from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait.
A sum score represents motor function with higher values on this scale represent a more severe stage of the disease.
Change is measurement at 16 weeks minus baseline measurement, negative scores indicate an improvement in Parkinson's motor symptoms.
|
Baseline, 16 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Amie Hiller, MD BS, VA Portland Health Care System, Portland, OR
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie parkinsoniane
- Malattie dei gangli basali
- Disturbi del movimento
- Sinucleinopatie
- Malattie Neurodegenerative
- Morbo di Parkinson
- Effetti fisiologici delle droghe
- Micronutrienti
- Vitamine
- Agenti di conservazione della densità ossea
- Ormoni e agenti regolatori del calcio
- Vitamina D
- Colecalciferolo
- Calcio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- B7051-W
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .